Tesaro (TSRO) this morning announced initial data from a Phase 1 study evaluating TSR-042, the company's anti-PD-1 antibody, in patients with microsatellite instability high endometrial cancer and non-small cell lung cancer, H.C. Wainwright analyst Edward White tells investors in a research note. Tesaro reported an overall response rate of 47%, which included seven partial responses. This compares favorably to the 36% ORR reported in the same setting with Merck's (MRK) Keytruda, White contends. He views this morning's data positively and continues to believe that Zejula in combination with Tesaro's immuno-oncology candidates could become commercially successful therapies and offer upside to the company's stock price. He reiterates a Buy rating on Tesaro with a $108 price target. The stock in midday trading is up 5% to $55.04.